Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders
Open accessThe DOI matches its Crossref record; 130 of the 131 references it cites were found in a registry or an index.
Abstract
Several clinical trials and experimental studies strongly suggest a place for Saccharomyces boulardii as a biotherapeutic agent for the prevention and treatment of several gastrointestinal diseases. S. boulardii mediates responses resembling the protective effects of the normal healthy gut flora. The multiple mechanisms of action of S. boulardii and its properties may explain its efficacy and beneficial effects in acute and chronic gastrointestinal diseases that have been confirmed by clinical trials. Caution should be taken in patients with risk factors for adverse events. This review discusses the evidence for efficacy and safety of S. boulardii as a probiotic for the prevention and therapy of gastrointestinal disorders in humans.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Numerous clinical studies have shown that Saccharomyces boulardiia nonpathogenic probiotic yeast isolated from the peel of fruits [151], is more effective than other probiotics, such as Lactobacillus and Bifidobacterium, in restoring the intestinal microbiota [152,153].”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [153]
Citations
Cites
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Antibiotic-Associated Diarrhea
Bartlett, J. G. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp011603 · Cited by 1,197 · cited 1×
“AAD is defined as otherwise unexplained diarrhea that occurs in association with the administration of antibiotics [Bartlett, 2002].”
BackgroundGuarino, A., Ashkenazi, S., Gendrel, D., Lo Vecchio, A., Shamir, R., & Szajewska, H. (2014) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000375 · Cited by 935
Probiotics and the gut microbiota in intestinal health and disease
Gareau, M. G., Sherman, P. M., & Walker, W. A. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.117 · Cited by 907 · cited 3×
“Saccharomyces boulardii as a probiotic An increasing number of potential health benefits are being attributed to probiotic treatments [Gareau et al. 2010; Szajewska et al. 2006].”
BackgroundMcFarland, L. V. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00465.x · Cited by 872 · cited 2×
“Several pieces of evidence suggest that S. boulardii represents the most effective probiotic that can prevent or, together with other agents, treat antibioticassociated diarrhea and recurrent CDI [McFarland, 2006] through many mechanisms (Table 2).”
BackgroundMethodInfluentialMcFarland, L. V. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510480037031 · Cited by 857 · cited 2×
“The significant relative reduction in recurrent CDI in adults taking S. boulardii compared with controls was evaluated in two RCTs and ranged between 19% and 33.3% [McFarland et al. 1994; Surawicz et al. 2000].”
MethodInfluentialKyne, L., Warny, M., Qamar, A., & Kelly, C. P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03592-3 · Cited by 804 · cited 2×
“…2009; Dahan et al. 2003; Mumy et al. 2008; Pant et al. 2007; Sougioultzis et al. 2006] 4) Blocks activation of ERK1/2 and MAP kinases [Chen et al. 2006; Kyne et al. 2001; Mumy et al. 2008; Sougioultzis et al. 2006] 5) Decreases NO and inhibits production of inducible NOS [Girard et al. 2005] 6)…”
BackgroundSaccharomyces boulardii in Maintenance Treatment of Crohn’s Disease
Guslandi, M., Mezzi, G., Sorghi, M., & Testoni, P. A. (2000) · Digestive Diseases and Sciences · doi:10.1023/a:1005588911207 · Cited by 723 · cited 2×
“[Guslandi et al. 2000].”
BackgroundReview article: yeast as probiotics – Saccharomyces boulardii
CZERUCKA, D., PICHE, T., & RAMPAL, P. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03442.x · Cited by 587 · cited 9×
“Several mechanisms of action have been identified directed against the host as well as pathogenic microorganisms and include regulation of intestinal microbial homeostasis, interference with the ability of pathogens to colonize and infect the mucosa, modulation of local and systemic immune responses, stabilization of…”
BackgroundInfluentialSystematic review and meta-analysis of Saccharomyces boulardii in adult patients
McFarland, L. V. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i18.2202 · Cited by 545 · cited 10×
“…of S. boulardii used is not reported consistently in all studies while in other studies the dose used is reported heterogeneously between different studies (e.g. number of organisms per 100 ml or number of organisms per day or colony forming units [cfu] per day or grams per day) [McFarland, 2010].”
BackgroundMethodInfluential
Research works printed but not linked: 10
- Bennani A. (1990) Randomised trial of Saccharomyces boulardii in the treatment of functional colon disorders. L’Objectif Medical 73: 56–61.
- 10.1097/00005176-199305000-00013 · doi:10.1097/00005176-199305000-00013 · Paper page
- Castaneda C., Garcia E., Santa Cruz M., Fernandez M., Monterrey P. (1995) Effects of Saccharomyces boulardii in children with chronic diarrhea, especially cases due to giardiasis. Rev Mex Pueric Pediatr 2: 12–16.
- Elmer G.W., Moyer K.A., Vega R., Surawicz C.M., Collier A.C., Hooton T.M., et al. (1995) Evaluation of Saccharomyces boulardii for patients with HIV-related chronic diarrhoea and in healthy volunteers receiving antifungals. Microb Ther 25: 23–31.
- 10.1046/j.1439-0507.1999.00449.x · DOI · Paper page
- 10.1111/j.1651-2227.2005.tb01848.x · doi:10.1111/j.1651-2227.2005.tb01848.x · Paper page
- Hochter W., Chase D., Hagenhoff G. (1990) Saccharomyces boulardii in acute adult diarrhea: efficacy and tolerability of treatment. Munch Med Wschr 132: 188–192.
- Kollaritsch H., Kremsner P., Wiedermann G., Scheiner O. (1989) Prevention of traveller’s diarrhea: comparison of different non-antibiotic preparations. Travel Med Internat 7: 9–18.
- Maupas J.L., Champemont P., Delforge M. (1983) Treatment of irritable bowel syndrome with Saccharomyces boulardii: a double-blind, placebo-controlled study. Med Chir Dig 12: 77–79.
- Schwenzer V.B. (1998) Saccharomyces boulardii. Deutsche Apotheker Zeitung 138: 75–77.
Cited by
Probiotics, prebiotics and synbiotics- a review
Pandey, K. R., Naik, S. R., & Vakil, B. V. (2015) · Journal of Food Science and Technology · doi:10.1007/s13197-015-1921-1 · Cited by 1,291
“Use of various probiotic species like S. boulardii, Lactobacillus casei and Bifidobacterium bifidum has shown promising results (Kelesidis and Pothoulakis 2012).”
BackgroundThe Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders
Socała, K., Doboszewska, U., Szopa, A., Serefko, A., Włodarczyk, M., Zielińska, A., Poleszak, E., Fichna, J., & Wlaź, P. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105840 · Cited by 857
Microbiome and Human Health: Current Understanding, Engineering, and Enabling Technologies
Aggarwal, N., Kitano, S., Puah, G. R. Y., Kittelmann, S., Hwang, I. Y., & Chang, M. W. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00431 · Cited by 508
van Zyl, W. F., Deane, S. M., & Dicks, L. M. T. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1831339 · Cited by 340
Human microbiome: an academic update on human body site specific surveillance and its possible role
Dekaboruah, E., Suryavanshi, M. V., Chettri, D., & Verma, A. K. (2020) · Archives of Microbiology · doi:10.1007/s00203-020-01931-x · Cited by 336
Metadata
- Authors
- Kelesidis, T., & Pothoulakis, C.
- Affiliations
- University of California, Los Angeles (US)
- Venue
- Therapeutic Advances in Gastroenterology
- Publisher
- SAGE Publications
- Published
- 2011-11-11
- Volume
- 5
- Issue
- 2
- Pages
- 111-125
- ISSN
- 1756-283X (ISSN-L)
- 1756-2848
- PMC
- PMC3296087
- OpenAlex
- W2008639012
- Cited by
- 377
- References
- 131
- Citations by year
- 2026: 44 · 2025: 44 · 2024: 40 · 2023: 26 · 2022: 45 · 2021: 42 · 2020: 21 · 2019: 20 · 2018: 19 · 2017: 24 · 2016: 14 · 2015: 19 · 2014: 11 · 2013: 6 · 2012: 2
- FWCI
- 8.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Therapeutic Advances in Gastroenterology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR000124)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- Saccharomyces boulardii, probiotics, gastrointestinal diseases, biologic therapy, gut microbiota, mechanism of action, efficacy, safety, adverse events
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. https://app.cochat.ai/papers/10.1177/1756283x11428502
- The paper
- Kelesidis, T., & Pothoulakis, C. (2012). Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therapeutic Advances in Gastroenterology. https://doi.org/10.1177/1756283x11428502
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.